Laminar Pharma is a pioneering biopharmaceutical company that focuses on the discovery, rational design and development of a new generation of medicines that act through the innovative therapeutic strategy known as “Membrane-Lipid Therapy” (MLT). Laminar Pharma arose in 2006 as an academic spin-off to commercially develop new scientific know-how and applications generated by leading scientists at the University of the Balearic Islands (UIB) in Mallorca, Spain, headed by Prof. Pablo V. Escriba. Laminar Pharma aims to develop next-generation medicines, nutraceutical and cosmetic products based on the novel Membrane-Lipid Therapy (MLT) strategy, which targets membrane lipids and/or the structures they form, rather than directly targeting specific cellular proteins. MLT-based drugs specifically interact with and modulate the activity of key signal-transduction peripheral proteins involved in the pathogeny of serious diseases like cancer, CNS, inflammatory or metabolic diseases. Innovative MLT-based drugs will soon become reference treatments worldwide for serious diseases with important medical needs unmet, such as glioblastoma and other aggressive cancer malignancies, as well as neuro-degenerative, metabolic, cardiovascular or inflammatory diseases. These novel drugs will provide a safe and efficacious therapeutic alternative that will bring dramatic improvements in the clinical outcome and in the quality of life for an important number of patients with these pathologies.
View Top Employees from Laminar PharmaWebsite | http://www.laminarpharma.com |
Revenue | $2 million |
Employees | 30 (22 on RocketReach) |
Founded | 2006 |
Phone | (978) 631-0600 |
Technologies |
JavaScript,
HTML,
PHP
+28 more
(view full list)
|
Industry | Biotechnology Research, Biotechnology, Pharmaceuticals, Healthcare |
Web Rank | 18 Million |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies |
Looking for a particular Laminar Pharma employee's phone or email?
The Laminar Pharma annual revenue was $2 million in 2024.
Paula Fernández García is the Chief Scientific Officer of Laminar Pharma.
22 people are employed at Laminar Pharma.
The NAICS codes for Laminar Pharma are [325, 32, 3254].
The SIC codes for Laminar Pharma are [28, 283].